Meda Acquires North Amercian Rights to Potential Blockbuster from BDSI

By Business Review Editor

Pharma Deals Review: Vol 2007 Issue 88 (Table of Contents)

Published: 7 Oct-2007

DOI: 10.3833/pdr.v2007.i88.278     ISSN: 1756-7874

Section: Licensing



Meda entered into an exclusive and perpetual license agreement with BioDelivery Sciences International (BDSI) to market BEMA(TM) Fentanyl for the treatment of breakthrough cancer pain in Canada, Mexico and US...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details